The effects of latamoxef, XXXX , and @entity2891 on platelet function and coagulation in normal volunteers.

@entity1 @entity2697 @entity1423 @entity857 @entity3524 @entity2891 @entity3399
A bleeding diathesis characterized by in-vitro @entity1423 and prolongation of the template bleeding time (TBT) has been reported in @entity1 receiving latamoxef ( @entity3399 ), but not @entity3524 or @entity2891 . Hypoprothrombinaemia has been associated with the use of both latamoxef and @entity2891 in seriously ill and malnourished @entity1 . We administered either latamoxef, @entity3524 or @entity2891 intravenously, at dosages within the range recommended by each manufacturer, to 14 normal volunteers. Latamoxef caused a dose and time dependent @entity1423 characterized in vitro by @entity1423 to @entity857 and in vivo by prolongation of the template bleeding time. In two out of two subjects, a single 4 g dose of @entity3399 caused neither prolongation of template bleeding times nor aggregation abnormalities. Two out of two subjects receiving latamoxef 6 g/day for six days had progressive prolongation of bleeding times to 12 and 15 min. Two additional subjects receiving latamoxef 12 g/day for four days had prolongation of template bleeding times to greater than 20 min. Of four subjects receiving @entity3524 12 g/day for seven days, none had prolongation of template bleeding times or @entity1423 . Of four subjects receiving @entity2891 6 g/day, none had significant prolongation of template bleeding times and one had @entity1423 attributed to inadvertent @entity2697 ingestion. Prolongation of the prothrombin time or activated partial thromboplastin time did not occur in any of the 14 volunteers. Latamoxef is more likely to interfere with platelet function than either @entity3524 or @entity2891 .
